An interventional study of High dosage, high intensity motor rehabilitation in Stroke and Hemiplegia and Hemiparesis, sponsored by Adi Negev-Nahalat Eran. Recruiting at 2 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Adi Negev-Nahalat Eran · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Stroke with a site in Israel — 12 open to participants now, 21 under way, 3 of them phase 3. Stroke · Israel.
Among the 127 studies in Stroke with a site in Israel, this one is the 51st largest by planned enrollment of the 86 interventional ones that give a count, is one of 4 that started in 2025, is one of 46 with no phase, reaches primary completion later than 10 of the 20 other live ones, and was the 121st registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →12 of the 127 studies in Stroke with a site in Israel are open now. Recruiting first, the newest first:
Motion Informatics LTD · Sites in Israel
Ages 18+
Eli Lilly and Company · Sites in Israel, Argentina, Australia and 35 more countries
Ages 50+
Adi Negev-Nahalat Eran · Sites in Israel
Ages 18–85 · Healthy volunteers
Adi Negev-Nahalat Eran · Sites in Israel, Palestinian Territories
Ages 18–85 · Healthy volunteers
Assaf-Harofeh Medical Center · Sites in Israel
Ages 50–85
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 14 · Phase 3 24 · Phase 4 2
First in 2000; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 72 across the 86 interventional studies, 196 across the 36 observational. Of the 69 that completed or were terminated, 21 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 127 have an industry lead sponsor. The 10 most frequent:
Adi Negev-Nahalat Eran is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Adi Negev-Nahalat Eran has 3 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
5 of the studies in Stroke with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07404761Motion Informatics LTDSafety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments | 2026-12-30 |
| NCT06441552Adi Negev-Nahalat EranThe Natural History of Recovery After Stroke | 2027-01 |
| NCT06497881Adi Negev-Nahalat EranUpper Limb Movement Quality Following Stroke | 2027-01-01 |
| NCT07056049Adi Negev-Nahalat EranThe Efficacy of Additional Motor Training Dosage During the Early Stages Post Stroke on the Upper Extremity Recovery | 2027-01-15 |
| NCT06096831University of HaifaLiving With Stroke - Sustainable Utilization of Healthcare Services | 2027-03 |
Add all 5 to your calendar (.ics) → With an account.
Among the 127 studies in Stroke with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intervention abstract
Background: Stroke is the leading cause of long-term disability, and the second leading cause of death in the western world. Most stroke survivors will suffer from motor and cognitive disturbances for the rest of their life, which negatively affects their normal daily life.
Despite the decline in stroke-related mortality over the past decades, the outcome of rehabilitation programs does not improve, and is predictable regardless of the program used. Still, several human and animal studies show that high capacity of training in the early stages post stroke improve motor recovery. This notion is far from being well established.
Aim: Studying the effect of high-dosage, high-intensity training program in the subacute period on upper extremity motor recovery.
Population: Stroke survivors. Study duration: 6 months. Study protocol: Participants will receive additional technology-based upper extremity training for 120 min/day, 5d/w, 4 weeks. They will be monitored pre and post training, and 6 months post-stroke. Outcome measures will include clinical, kinematic and adherence measures (see complete list in the protocol).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive additional technology-based upper extremity training for 120 min/day, 5d/w, 4 weeks. The program will be tailored to their impairment level, and will be added to the usual treatment given during hospitalization.
Behavioral: High dosage, high intensity motor rehabilitation
This group is comprised of patients with similar characteristics and the intervention group will be compared to this group.
Participants will receive additional technology-based upper extremity training for 120 min/day, 5d/w, 4 weeks.
Fugl-Meyer upper extremity assessment (FM-UE)
The Upper Extremity Fugl-Meyer Assessment (UE-FMA) is a standardized clinical tool designed to evaluate motor impairment in the upper limb following a stroke. It is part of the broader Fugl-Meyer Assessment, one of the most widely used and validated scales in stroke rehabilitation research. The UE-FMA specifically assesses movement, coordination, and reflexes in the shoulder, elbow, forearm, wrist, and hand, with a maximum score of 66 points. The scale is divided into subcomponents, including upper limb movement (36 points), wrist (10 points), hand (14 points), and coordination/speed (6 points). Each item is scored on a 3-point ordinal scale (0 = cannot perform, 1 = performs partially, 2 = performs fully), offering a total score that reflects the level of motor impairment-higher scores indicate better motor function. The UE-FMA is valued for its reliability, sensitivity to impairment (rather than function), and its ability to track motor recovery over time.
Time frame: Enrollment, 1 month, 3 months, 6 months after enrollment
Action research arm test (ARAT)
The Action Research Arm Test (ARAT) is a standardized clinical tool used to assess upper limb function following stroke or neurological injury, with a focus on evaluating the ability to perform purposeful, goal-directed tasks. It consists of 19 items grouped into four subscales: grasp, grip, pinch, and gross movement, each designed to measure different aspects of upper limb activity. Tasks include actions such as picking up small blocks, pouring water, or moving objects across a table. Each item is scored on a 4-point ordinal scale ranging from 0 (no movement) to 3 (normal performance), yielding a maximum total score of 57. The ARAT captures the functional use of the hand and arm in a way that reflects real-world tasks, making it especially relevant for tracking meaningful improvements during rehabilitation. It is known for its high inter-rater and intra-rater reliability and is sensitive to changes in functional performance across a wide spectrum of impairment levels.
Time frame: Enrollment, 1 month, 3 months, 6 months after enrollment
Stroke Impact Scale (SIS) hand domain, version 2.0
The Stroke Impact Scale (SIS) hand domain, version 2.0, is a patient-reported outcome measure that assesses the perceived difficulty of using the affected hand in everyday tasks following a stroke. This domain includes five items that ask individuals to rate the difficulty of performing common activities such as carrying heavy objects, turning a doorknob, or picking up a coin. Each item is scored on a 5-point Likert scale ranging from 1 (could not do it at all) to 5 (not difficult at all), reflecting the patient's experience over the past week. Scores are converted to a 0-100 scale, with higher scores indicating better perceived hand function. The SIS hand domain captures the individual's perspective on the functional impact of stroke on daily activities, providing valuable insight into real-world hand use. It is frequently used in stroke rehabilitation studies to complement performance-based assessments and to evaluate patient-centered outcomes.
Time frame: Enrollment, 1 month, 3 months, 6 months after enrollment
Kinematics
Using reaching tasks that will be recorded using multiple high resolution video-cameras and analyzed using AI algorithm (OpenPose). Outcome measures that will be examined include: trajectory smoothness, reaching extent, shoulder-elbow synergy, movement time and deviation from trajectories of age matched healthy controls.
Time frame: Enrollment, 1 month, 3 months, 6 months
Upper extremity activity
Daily natural activity will be monitored for using IMUs (Movella DOT) worn on upper extremity and trunk for periods of up-to 6 hours.
Time frame: Enrollment and 3 months.
Time on task
Actual time spent training during a practice session.
Time frame: The measure will be recorded every single practice session, twice a day, 5 days a week. Total Time on Task will be calculated at the end of the intervention period, approximately 4 weeks.
Attendance
The rate in which a participant actively participated in the training sessions.
Time frame: The measure will be recorded every single practice session, twice a day, 5 days a week. Total attendance will be calculated at the end of the intervention period, approximately after 4 weeks.
Visual Analogue Scale for pain
The VAS is a self-report measure consisting of a 10 centimeter line with a statement at each end representing one extreme of pain intensity (No pain and pain as bad as it could possibly be). The participant gives their indication with a pen mark on the line corresponding to their present pain level. The higher the score, the worse the pain.
Time frame: The measure will be recorded before and after every single practice session, twice a day, 5 days a week. The mean pain level delta will be calculated at the end of the intervention period, approximately 4 weeks.
Rating of perceived exertion (RPE)
The revised category-ratio scale (0 to 10 scale) will be used to monitor and guide exercise intensity. Participants subjectively rate their level of exertion during exercise (American College of Sports Medicine, 2010). A higher score means higher exertion experienced by the participant during the session. It is not necessarily good or bad, it is just an indication of the effort.
Time frame: The measure will be recorded every single practice session, twice a day, 5 days a week.
The Intrinsic Motivation Inventory (IMI)
The IMI is a validated self-report tool used to assess intrinsic motivation toward a specific activity. It includes multiple subscales, with Interest/Enjoyment considered the primary indicator of intrinsic motivation. Items are rated on a 7-point Likert scale (1 = not at all true, 7 = very true), and subscale scores are averaged to produce interpretable values. Higher scores reflect greater intrinsic motivation, perceived competence, or effort, depending on the subscale.
Time frame: At the end of the intervention period for each participant (i.e. 4 weeks).
Berg Balance Scale (BBS)
Consists of 14 items for assessing static and dynamic balance and risk of falls for different populations. The test includes different tasks in various challenging positions and scored up to 56 points. A higher score indicated better balance and lower risk of falls.
Time frame: Only at enrollment.
Fatigue Severity Scale (FSS)
The 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders. A higher scale indicated higher fatigue level.
Time frame: At the end of the intervention period (i.e. 4 weeks)
Plan to share: Yes — The individual participant data to be shared will include de-identified information collected during the trial, such as demographic and baseline characteristics, intervention allocations, and all outcome measures used in both the primary and secondary analyses. In addition, supporting documentation will be provided to facilitate proper use of the data, including the study protocol, statistical analysis plan, informed consent form template, and a comprehensive data dictionary.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: The de-identified individual participant data and supporting documentation will be made available beginning six months after publication of the primary results and will remain accessible for a minimum of five years thereafter.
Access criteria: Qualified researchers with a scientifically sound proposal will be able to request access to the de-identified individual participant data and supporting documents, including the study protocol, statistical analysis plan, informed consent form template, and data dictionary. Access will be granted through a secure data repository following submission and approval of a data access request. Researchers will be required to sign a data use agreement outlining conditions for responsible data use, including maintaining confidentiality and using the data only for the approved purpose. Access will be provided through controlled mechanisms, such as registered user accounts or institutional credentials, depending on the repository's access procedures.
Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 18 months is below that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adi Negev-Nahalat Eran